Merck KGAA/Pfizer's Bavencio Failure Casts More Shade On Immunotherapy For Ovarian Cancer
Executive Summary
Phase III first-line JAVELIN Ovarian 100 study fails, but trial combining Bavencio with PARP inhbitor Talzenna in similar setting goes on.
You may also be interested in...
Roche's Tecentriq Disappoints In Ovarian Cancer Study
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay
European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.